Stay updated with breaking news from Mark Lanasa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tislelizumab demonstrated non-inferiority for overall survival and favorable safety profile versus sorafenib in global Phase 3 trialAdditional poster presentations show breadth of tislelizumab global clinical development program as single-agent treatment and in combinationCAMBRIDGE, Mass. & BASEL, Switzerland & BEIJ...
09.08.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the global ... Seite 1
27.04.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the ... Seite 1
Statistically significant and clinically meaningful improvement in overall survival achieved for tislelizumab and chemotherapy compared to placebo and chemotherapy Safety profile for the
Tislelizumab is now approved for eight indications in China BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative